Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective? Thomas B. KarasicMark A. RosenPeter J. O’Dwyer Review Article 18 July 2017 Pages: 661 - 671
Hyponatremia and V2 vasopressin receptor upregulation: a result of HSP90 inhibition Qiong YangFlorian PuhmChristian Nanoff Original Article Open access 04 August 2017 Pages: 673 - 684
Tunicamycin potentiates paclitaxel-induced apoptosis through inhibition of PI3K/AKT and MAPK pathways in breast cancer Shengshi HuangDi WangYikang Shi Original Article 04 August 2017 Pages: 685 - 696
The concept of platinum sensitivity could be applied to recurrent cervical cancer: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group Munetaka TakekumaKeita MoriToru Sugiyama Original Article 07 August 2017 Pages: 697 - 705
A phase II study of modified docetaxel, cisplatin, and S-1 (mDCS) chemotherapy for unresectable advanced gastric cancer Naoki UemuraShohei KikuchiJunji Kato Original Article 28 August 2017 Pages: 707 - 713
Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma Michael A. BadruddojaMarjorie PazziMichael Malek Ahmadi Original Article 14 August 2017 Pages: 715 - 721
Novel formulation of abiraterone acetate might allow significant dose reduction and eliminates substantial positive food effect Tamás SolymosiZsolt ÖtvösHristos Glavinas Original Article 03 August 2017 Pages: 723 - 728
Comparison of the RECIST and EORTC PET criteria in the tumor response assessment: a pooled analysis and review Jung Han KimBum Jun KimHyeong Su Kim Original Article 05 August 2017 Pages: 729 - 735
Absence of cardiotoxicity with prolonged treatment and large accumulating doses of pegylated liposomal doxorubicin N. BlankI. LaskovL. Rudski Original Article 11 August 2017 Pages: 737 - 743
Allicin ameliorates doxorubicin-induced cardiotoxicity in rats via suppression of oxidative stress, inflammation and apoptosis Mohamed M. Abdel-DaimOmnia E. kilanyAmal A. M. Ahmed Original Article 07 August 2017 Pages: 745 - 753
A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men Richard MarkusVincent ChowVladimir Hanes Original Article Open access 01 September 2017 Pages: 755 - 763
MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells Azam RajabpourAli AfgarLadan Teimoori-Toolabi Original Article 08 September 2017 Pages: 765 - 775
Interim analysis of a phase II trial evaluating the safety and efficacy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer Katsuki DannoTaishi HataColorectal Cancer Treatment Group (MCSGO) Original Article 19 August 2017 Pages: 777 - 785
Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value Keith M. SkubitzAnne H. BlaesGary S. Francis Original Article 30 August 2017 Pages: 787 - 798
Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea Kyong Joo LeeJae Hee ChoWoo Jin Lee Original Article 07 September 2017 Pages: 799 - 805
Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy Shigenori KadowakiToshiki MasuishiKei Muro Original Article 18 August 2017 Pages: 807 - 813
Superactive human leptin antagonist (SHLA), triple Lan1 and quadruple Lan2 leptin mutein as a promising treatment for human folliculoma E. FiedorE. L. Gregoraszczuk Original Article Open access 31 August 2017 Pages: 815 - 827
Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia Islem Ben HassineHanene GharbiSamia Menif Original Article 23 August 2017 Pages: 829 - 839
Comparison of adverse events following injection of original or generic docetaxel for the treatment of breast cancer Nao TagawaErika SugiyamaHitoshi Sato Original Article 01 September 2017 Pages: 841 - 849
Significance of glucocorticoid receptor expression in patients with non-small cell lung cancer treated with pemetrexed-based chemotherapy Xin-min ZhaoJing ZhaoJia-lei Wang Clinical Trial Report 28 July 2017 Pages: 851 - 860
Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition Gayathri SrinivasanGurjit Singh SidhuRobert Hromas Short Communication Open access 29 July 2017 Pages: 861 - 867
Continuous low plasma concentrations of everolimus provides equivalent efficacy to oral daily dosing in mouse xenograft models of human cancer Laurent LabordeFatos OzPaul McSheehy Short Communication 04 August 2017 Pages: 869 - 878
Optimism and the continued promise of maintenance chemotherapy John P. MichaBram GoldsteinMaurie Markman Letter to the Editor 07 September 2017 Pages: 879 - 880
